| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA479: Reslizumab for treating severe eosinophilic asthma |
|
Medicine details |
|
| Medicine name | reslizumab (Cinqaero®) |
| Formulation | 10 mg/ml solution for infusion |
| Reference number | 934 |
| Indication | Add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment |
| Company | TEVA UK Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/07/2016 |
| NICE guidance | |